117 related articles for article (PubMed ID: 21452041)
21. Activation of FOXO3a suggests good prognosis of patients with radically resected gastric cancer.
Yu S; Yu Y; Sun Y; Wang X; Luo R; Zhao N; Zhang W; Li Q; Cui Y; Wang Y; Li W; Liu T
Int J Clin Exp Pathol; 2015; 8(3):2963-70. PubMed ID: 26045805
[TBL] [Abstract][Full Text] [Related]
22. Deregulation of FOXO3A during prostate cancer progression.
Shukla S; Shukla M; Maclennan GT; Fu P; Gupta S
Int J Oncol; 2009 Jun; 34(6):1613-20. PubMed ID: 19424579
[TBL] [Abstract][Full Text] [Related]
23. PFTK1 regulates cell proliferation, migration and invasion in epithelial ovarian cancer.
Zhang W; Liu R; Tang C; Xi Q; Lu S; Chen W; Zhu L; Cheng J; Chen Y; Wang W; Zhong J; Deng Y
Int J Biol Macromol; 2016 Apr; 85():405-16. PubMed ID: 26772918
[TBL] [Abstract][Full Text] [Related]
24. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications.
Park SH; Jang KY; Kim MJ; Yoon S; Jo Y; Kwon SM; Kim KM; Kwon KS; Kim CY; Woo HG
Oncotarget; 2015 Dec; 6(42):44819-31. PubMed ID: 26540566
[TBL] [Abstract][Full Text] [Related]
25. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
26. A missense mutation in the transcription factor Foxo3a causes teratomas and oocyte abnormalities in mice.
Youngson NA; Vickaryous N; van der Horst A; Epp T; Harten S; Fleming JS; Khanna KK; de Kretser DM; Whitelaw E
Mamm Genome; 2011 Apr; 22(3-4):235-48. PubMed ID: 21347845
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer.
Wang Y; Wang Y; Shen L; Pang Y; Qiao Z; Liu P
Oncol Rep; 2012 Apr; 27(4):1156-62. PubMed ID: 22266777
[TBL] [Abstract][Full Text] [Related]
29. Spy1 participates in the proliferation and apoptosis of epithelial ovarian cancer.
Lu S; Liu R; Su M; Wei Y; Yang S; He S; Wang X; Qiang F; Chen C; Zhao S; Zhang W; Xu P; Mao G
J Mol Histol; 2016 Feb; 47(1):47-57. PubMed ID: 26644004
[TBL] [Abstract][Full Text] [Related]
30. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
[TBL] [Abstract][Full Text] [Related]
31. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.
Fang Y; Li Z; Wang X; Zhang S
Tumour Biol; 2012 Dec; 33(6):2299-306. PubMed ID: 22923389
[TBL] [Abstract][Full Text] [Related]
32. Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases.
Concin N; Hefler L; van Bavel J; Mueller-Holzner E; Zeimet A; Daxenbichler G; Speiser P; Hacker N; Marth C
Gynecol Oncol; 2003 Apr; 89(1):9-15. PubMed ID: 12694648
[TBL] [Abstract][Full Text] [Related]
33. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
34. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation.
Shiota M; Song Y; Yokomizo A; Kiyoshima K; Tada Y; Uchino H; Uchiumi T; Inokuchi J; Oda Y; Kuroiwa K; Tatsugami K; Naito S
Clin Cancer Res; 2010 Dec; 16(23):5654-63. PubMed ID: 21138866
[TBL] [Abstract][Full Text] [Related]
35. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
[TBL] [Abstract][Full Text] [Related]
36. [Effects of AG1478 on the expression of FOXM1 gene via FOXO3a in non-small cell lung cancer cells].
Gong XD; Yuan HH; Wang JY; Guo YH; Shi J; Jiang B
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):572-8. PubMed ID: 24314213
[TBL] [Abstract][Full Text] [Related]
37. FoxO3a preferentially induces p27Kip1 expression while impairing muscle precursor cell-cycle progression.
Rathbone CR; Booth FW; Lees SJ
Muscle Nerve; 2008 Jan; 37(1):84-9. PubMed ID: 17894357
[TBL] [Abstract][Full Text] [Related]
38. [Effect of Foxo3a gene over-expression on the development of rat ovarian granulose cells and in prevention of cisplatin-induced ovarian damage in rats].
Yang Y; Fang LH; Wang XF
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Jun; 36(6):796-801. PubMed ID: 27320881
[TBL] [Abstract][Full Text] [Related]
39. DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpression in lung cancer.
Yang YC; Tang YA; Shieh JM; Lin RK; Hsu HS; Wang YC
J Thorac Oncol; 2014 Sep; 9(9):1305-15. PubMed ID: 25122426
[TBL] [Abstract][Full Text] [Related]
40. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
